FRAZER, Pa. Cephalon plans to buy a generic drug maker based in Switzerland for $590 million, the U.S. drug maker announced Monday.
Cephalon said it would buy Mepha, a private company that makes more than 120 generics and branded generics. The company had sales of 400 million Swiss francs in 2009.
Cephalon said the acquisition would diversify its business mix, double the size of its international business and provide a platform for launching current and future products in new, developed and emerging markets.
“The addition of Mepha will transform our international business overnight, expanding our ability to serve global markets and reach patients in new territories for the first time,” Cephalon chairman and CEO Frank Baldino said. “With this deal, we now serve all three types of pharmaceutical markets: proprietary branded, generic and branded generic.”